CN111811910A - 一种石蜡切片钙盐染色套染苏木素-伊红试剂盒及其染色方法 - Google Patents
一种石蜡切片钙盐染色套染苏木素-伊红试剂盒及其染色方法 Download PDFInfo
- Publication number
- CN111811910A CN111811910A CN202010622859.1A CN202010622859A CN111811910A CN 111811910 A CN111811910 A CN 111811910A CN 202010622859 A CN202010622859 A CN 202010622859A CN 111811910 A CN111811910 A CN 111811910A
- Authority
- CN
- China
- Prior art keywords
- staining
- hematoxylin
- 5min
- solution
- eosin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000010186 staining Methods 0.000 title claims abstract description 69
- 159000000007 calcium salts Chemical class 0.000 title claims abstract description 55
- 239000012188 paraffin wax Substances 0.000 title claims abstract description 44
- 238000007447 staining method Methods 0.000 title claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 71
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 claims abstract description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000000243 solution Substances 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 38
- 238000005406 washing Methods 0.000 claims abstract description 37
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims abstract description 35
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229910052709 silver Inorganic materials 0.000 claims abstract description 32
- 239000004332 silver Substances 0.000 claims abstract description 32
- 239000008096 xylene Substances 0.000 claims abstract description 31
- 235000019441 ethanol Nutrition 0.000 claims abstract description 26
- 238000004043 dyeing Methods 0.000 claims abstract description 21
- 239000012153 distilled water Substances 0.000 claims abstract description 19
- 230000004069 differentiation Effects 0.000 claims abstract description 15
- 239000012192 staining solution Substances 0.000 claims abstract description 11
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 claims abstract description 9
- 208000002109 Argyria Diseases 0.000 claims abstract description 3
- 230000007935 neutral effect Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 6
- 230000001678 irradiating effect Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 3
- 230000008021 deposition Effects 0.000 abstract description 12
- 230000036285 pathological change Effects 0.000 abstract description 6
- 231100000915 pathological change Toxicity 0.000 abstract description 6
- 238000005457 optimization Methods 0.000 abstract description 3
- 239000011521 glass Substances 0.000 description 12
- 230000002792 vascular Effects 0.000 description 12
- 208000004434 Calcinosis Diseases 0.000 description 6
- 230000003902 lesion Effects 0.000 description 5
- 230000037311 normal skin Effects 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000011892 Von Kossa's method Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000029088 Phosphorus metabolism disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N1/31—Apparatus therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N2001/302—Stain compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明公开了一种石蜡切片钙盐染色套染苏木素‑伊红试剂盒,该试剂盒包括由以下组分构成:二甲苯、无水乙醇、Von kossa银染液、海波溶液、苏木素染色液、伊红染色液、苏木素分化液、苏木素返蓝液;一种石蜡切片钙盐染色套染苏木素‑伊红试剂盒的染色方法,包括如下步骤构成,S1:脱蜡至水:依次将切片放入二甲苯Ⅰ15min、二甲苯Ⅱ15min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、85%酒精5min、75%酒精5min、蒸馏水洗,本发明的石蜡切片钙盐染色(Von kossa银法)套染苏木素‑伊红(HE)试剂盒及其染色方法通过技术优化将钙盐染色和HE染色相结合,应用于各种组织钙盐沉积和病变情况的判断,与单纯石蜡切片钙盐染色,HE染色相比,结果对比明显,染色清晰,易于判断。
Description
技术领域
本发明涉及生物医药应用领域,尤其是涉及一种石蜡切片钙盐染色套染苏木素-伊红试剂盒及其染色方法。
背景技术
钙质是人体不可缺少的一大营养素,一旦缺乏,可能因为骨骼不坚固出现骨折等问题。临床上与之相似的一种病症被称为钙质沉着。钙质沉着症是不溶性钙盐沉积于组织所产生的疾病。分为特发性、转移性和营养不良性。特发性钙质沉着症多原因不明,转移性钙质沉着症继发于钙磷代谢障碍性疾病,如甲状旁腺功能亢进、多发性骨髓瘤、肾功能不全使磷酸盐潴留等。营养不良性钙质沉着症多继发于皮肤或组织损伤。现临床上大多慢性病会伴随血管钙质沉积。使用石蜡切片进行钙盐染色(Von kossa银法)检测钙质沉积是目前最简单,直接,有效的方法。苏木精-伊红(HE)染色是组织学、胚胎学、病理学和科研中最基本、使用最广泛的技术方法。是区分和辨别正常组织和病变组织最简单、快捷和直接的方法。由于临床上获取样本后,必须制作多张冰冻切片,石蜡切片等进行各种染色,已备观察结果。由于临床获得样本较少,且个体差异较大,对样本取材要求较高,若染色结果不理想,需要进行重复染色,造成样本量不足做更多染色检测。
为此,提出一种石蜡切片钙盐染色套染苏木素-伊红试剂盒及其染色方法。
发明内容
本发明的目的在于提供一种石蜡切片钙盐染色套染苏木素-伊红试剂盒及其染色方法,该试剂盒染色过程简单快捷,可以用于同一张切片上染色显示钙盐沉积及病变情况,本发明的石蜡切片钙盐染色(Von kossa银法)套染HE可减少组织制备过程,染色步骤少,实验时间短,稳定性高,实验结果对比明显,所呈现的结果信息远远高于传统单染,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:
一种石蜡切片钙盐染色套染苏木素-伊红试剂盒,该试剂盒包括由以下组分构成:二甲苯、无水乙醇、Von kossa银染液、海波溶液、苏木素染色液、伊红染色液、苏木素分化液、苏木素返蓝液。
一种石蜡切片钙盐染色套染苏木素-伊红试剂盒的染色方法,包括如下步骤构成:
S1:脱蜡至水:依次将切片放入二甲苯Ⅰ15min、二甲苯Ⅱ15min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、85%酒精5min、75%酒精5min、蒸馏水洗;
S2:切片入Von Kossa银溶液,强光照射30min,蒸馏水洗1min;
S3:切片入海波溶液处理2min,蒸馏水洗1min;
S4:苏木素染色3-5min,流水稍冲洗;
S5:苏木素分化液分化30sec,观察分化效果,流水稍冲洗;
S6:苏木素返蓝液返蓝1min,流水稍冲洗;
S7:镜检着色满意后入伊红染色液染色3-5min;
S8:95%酒精Ⅰ5min、95%酒精Ⅱ5min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、二甲苯Ⅰ、二甲苯Ⅱ,中性树胶封片。
优选的,所述S8中二甲苯Ⅰ5min、二甲苯Ⅱ10min。
优选的,所述S1至S8过程中,切片水洗及染色时,染色所需溶液要完全没过切片整体。
与现有技术相比,本发明的有益效果是:
1.一张切片显示多种信息,本发明的石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)试剂盒及其染色方法通过技术优化将钙盐染色和HE染色相结合,应用于各种组织钙盐沉积和病变情况的判断,与单纯石蜡切片钙盐染色,HE染色相比,结果对比明显,染色清晰,易于判断。
2.结果稳定,易推广,本发明的石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)试剂盒及其染色方法减少组织制备过程,染色步骤少,实验时间缩短,稳定性高,实验结果直观可靠,所提供的信息量高于传统单独染色。
3.扩大了石蜡切片应用范围,节省资源和时间,本发明的石蜡切片钙盐染色(Vonkossa银法)套染苏木素-伊红(HE)试剂盒及其染色方法同时具备判断钙盐沉积情况和病变情况,节约材料和制样及观察时间。
附图说明
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案,下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图是本发明的一些实施方式,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为本发明的血管组织钙盐染色(Von kossa银法)套染苏木素-伊红(HE)染色一图;
图2为本发明的血管组织钙盐染色(Von kossa银法)套染苏木素-伊红(HE)染色二图;
图3为本发明的皮肤组织钙盐染色(Von kossa银法)套染苏木素-伊红(HE)染色一图;
图4为本发明的皮肤组织钙盐染色(Von kossa银法)套染苏木素-伊红(HE)染色二图;
图5为本发明实施例一中的正常血管组织石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)染色图;
图6为本发明实施例二中的病变血管组织石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)染色图;
图7为本发明实施例三中的正常皮肤组织石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)染色图;
图8为本发明实施例四中的病变皮肤组织石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)染色图。
具体实施方式
下面将结和本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
请参阅图1至图8,本发明提供四种实施例:
实施例一:
正常血管组织钙盐染色(Von kossa银法)套染苏木素-伊红(HE)
多聚甲醛固定,石蜡包埋正常血管组织,石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)步骤如下:
S1.脱蜡至水:采用常规方法制备正常血管组织石蜡切片,依次将切片放入二甲苯Ⅰ15min、二甲苯Ⅱ15min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、85%酒精5min、75%酒精5min、蒸馏水洗;
S2.切片入Von Kossa银溶液,强光照射30min,蒸馏水洗1min;
S3.切片入海波溶液处理2min,蒸馏水洗1min;
S4.苏木素染色3-5min,流水稍冲洗;
S5.苏木素分化液分化30sec(观察分化效果),流水稍冲洗;
S6.苏木素返蓝液返蓝1min,流水稍冲洗;
S7.镜检着色满意后入伊红染色液染色3-5min;
S8.95%酒精Ⅰ5min、95%酒精Ⅱ5min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、二甲苯Ⅰ5min、二甲苯Ⅱ10min,中性树胶封片。
正常血管组织石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)结果如图5所示,组织结构清晰,无黑色沉淀,说明无钙盐沉积。
实施例二:
病变血管组织钙盐染色(Von kossa银法)套染苏木素-伊红(HE)
多聚甲醛固定,石蜡包埋病变血管组织,石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)步骤如下:
S1.脱蜡至水:采用常规方法制备病变血管组织石蜡切片,依次将切片放入二甲苯Ⅰ15min、二甲苯Ⅱ15min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、85%酒精5min、75%酒精5min、蒸馏水洗;
S2.切片入Von Kossa银溶液,强光照射30min,蒸馏水洗1min;
S3.切片入海波溶液处理2min,蒸馏水洗1min;
S4.苏木素染色3-5min,流水稍冲洗;
S5.苏木素分化液分化30sec(观察分化效果),流水稍冲洗;
S6.苏木素返蓝液返蓝1min,流水稍冲洗;
S7.镜检着色满意后入伊红染色液染色3-5min;
S8.95%酒精Ⅰ5min、95%酒精Ⅱ5min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、二甲苯Ⅰ5min、二甲苯Ⅱ10min,中性树胶封片。
病变血管组织石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)结果如图6所示,组织结构清晰,血管增生,有大量黑色沉淀,说明有钙盐沉积。
实施例三:
正常皮肤组织钙盐染色(Von kossa银法)套染苏木素-伊红(HE)
多聚甲醛固定,石蜡包埋正常皮肤组织,石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)步骤如下:
S1.脱蜡至水:采用常规方法制备正常皮肤组织石蜡切片,依次将切片放入二甲苯Ⅰ15min、二甲苯Ⅱ15min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、85%酒精5min、75%酒精5min、蒸馏水洗;
S2.切片入Von Kossa银溶液,强光照射30min,蒸馏水洗1min;
S3.切片入海波溶液处理2min,蒸馏水洗1min;
S4.苏木素染色3-5min,流水稍冲洗;
S5.苏木素分化液分化30sec(观察分化效果),流水稍冲洗;
S6.苏木素返蓝液返蓝1min,流水稍冲洗;
S7.镜检着色满意后入伊红染色液染色3-5min;
S8.95%酒精Ⅰ5min、95%酒精Ⅱ5min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、二甲苯Ⅰ5min、二甲苯Ⅱ10min,中性树胶封片。
正常皮肤组织石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)结果如图7所示,组织结构清晰,无黑色沉淀,说明无钙盐沉积。
实施例四:
病变皮肤组织钙盐染色(Von kossa银法)套染苏木素-伊红(HE)
多聚甲醛固定,石蜡包埋病变皮肤组织,石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)步骤如下:
S1.脱蜡至水:采用常规方法制备病变皮肤组织石蜡切片,依次将切片放入二甲苯Ⅰ15min、二甲苯Ⅱ15min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、85%酒精5min、75%酒精5min、蒸馏水洗;
S2.切片入Von Kossa银溶液,强光照射30min,蒸馏水洗1min;
S3.切片入海波溶液处理2min,蒸馏水洗1min;
S4.苏木素染色3-5min,流水稍冲洗;
S5.苏木素分化液分化30sec(观察分化效果),流水稍冲洗;
S6.苏木素返蓝液返蓝1min,流水稍冲洗;
S7.镜检着色满意后入伊红染色液染色3-5min。
S8.95%酒精Ⅰ5min、95%酒精Ⅱ5min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、二甲苯Ⅰ5min、二甲苯Ⅱ10min,中性树胶封片。
病变皮肤组织石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)结果如图8所示,组织结构清晰,伴随大量炎症浸润,有大量黑色沉淀,说明有钙盐沉积。
有益效果:
1.一张切片显示多种信息,本发明的石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)试剂盒及其染色方法通过技术优化将钙盐染色和HE染色相结合,应用于各种组织钙盐沉积和病变情况的判断,与单纯石蜡切片钙盐染色,HE染色相比,结果对比明显,染色清晰,易于判断。
2.结果稳定,易推广,本发明的石蜡切片钙盐染色(Von kossa银法)套染苏木素-伊红(HE)试剂盒及其染色方法减少组织制备过程,染色步骤少,实验时间缩短,稳定性高,实验结果直观可靠,所提供的信息量高于传统单独染色。
3.扩大了石蜡切片应用范围,节省资源和时间,本发明的石蜡切片钙盐染色(Vonkossa银法)套染苏木素-伊红(HE)试剂盒及其染色方法同时具备判断钙盐沉积情况和病变情况,节约材料和制样及观察时间。
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (4)
1.一种石蜡切片钙盐染色套染苏木素-伊红试剂盒,其特征在于:该试剂盒包括由以下组分构成:二甲苯、无水乙醇、Von kossa银染液、海波溶液、苏木素染色液、伊红染色液、苏木素分化液、苏木素返蓝液。
2.根据权利要求1所述的一种石蜡切片钙盐染色套染苏木素-伊红试剂盒的染色方法,其特征在于,包括如下步骤构成:
S1:脱蜡至水:依次将切片放入二甲苯Ⅰ15min、二甲苯Ⅱ15min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、85%酒精5min、75%酒精5min、蒸馏水洗;
S2:切片入Von Kossa银溶液,强光照射30min,蒸馏水洗1min;
S3:切片入海波溶液处理2min,蒸馏水洗1min;
S4:苏木素染色3-5min,流水稍冲洗;
S5:苏木素分化液分化30sec,观察分化效果,流水稍冲洗;
S6:苏木素返蓝液返蓝1min,流水稍冲洗;
S7:镜检着色满意后入伊红染色液染色3-5min;
S8:95%酒精Ⅰ5min、95%酒精Ⅱ5min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、二甲苯Ⅰ、二甲苯Ⅱ,中性树胶封片。
3.根据权利要求2所述的一种石蜡切片钙盐染色套染苏木素-伊红试剂盒的染色方法,其特征在于:所述S8中二甲苯Ⅰ5min、二甲苯Ⅱ10min。
4.根据权利要求2所述的一种石蜡切片钙盐染色套染苏木素-伊红试剂盒的染色方法,其特征在于:所述S1至S8过程中,切片水洗及染色时,染色所需溶液要完全没过切片整体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010622859.1A CN111811910A (zh) | 2020-07-01 | 2020-07-01 | 一种石蜡切片钙盐染色套染苏木素-伊红试剂盒及其染色方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010622859.1A CN111811910A (zh) | 2020-07-01 | 2020-07-01 | 一种石蜡切片钙盐染色套染苏木素-伊红试剂盒及其染色方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111811910A true CN111811910A (zh) | 2020-10-23 |
Family
ID=72855966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010622859.1A Pending CN111811910A (zh) | 2020-07-01 | 2020-07-01 | 一种石蜡切片钙盐染色套染苏木素-伊红试剂盒及其染色方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111811910A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113740137A (zh) * | 2021-09-30 | 2021-12-03 | 山东骏腾医疗科技有限公司 | 一种病理组织切片染色试剂盒 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110753869A (zh) * | 2017-06-15 | 2020-02-04 | 日光石科技有限公司 | 用于特异染色的过程记录玻片 |
-
2020
- 2020-07-01 CN CN202010622859.1A patent/CN111811910A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110753869A (zh) * | 2017-06-15 | 2020-02-04 | 日光石科技有限公司 | 用于特异染色的过程记录玻片 |
Non-Patent Citations (12)
Title |
---|
孙小蓉 汪键 主编: "《DNA定量细胞学》", 31 January 2018, pages: 31 - 32 * |
张翠霞等: "病理快速冷冻切片染色的质控切片制备", 《中国组织化学与细胞化学杂志》 * |
张翠霞等: "病理快速冷冻切片染色的质控切片制备", 《中国组织化学与细胞化学杂志》, no. 05, 7 November 2018 (2018-11-07) * |
覃春美等: "2型糖尿病肾病大鼠肾动脉上BMP2/Smad1/Runx2/Osterix信号通路的激活", 《中国动脉硬化杂志》 * |
覃春美等: "2型糖尿病肾病大鼠肾动脉上BMP2/Smad1/Runx2/Osterix信号通路的激活", 《中国动脉硬化杂志》, no. 10, 31 October 2016 (2016-10-31), pages 983 - 988 * |
郑建华等: "常规苏木精-伊红HE染色与环保试剂HE染色的效果对比", 《中国医学装备》 * |
郑建华等: "常规苏木精-伊红HE染色与环保试剂HE染色的效果对比", 《中国医学装备》, no. 04, 24 April 2019 (2019-04-24) * |
陈杰主编: "《临床病理科诊断常规》", 30 June 2020, pages: 683 - 684 * |
黄洁平等: "β-羟丁酸对高磷诱导的血管钙化的影响", 《岭南急诊医学杂志》 * |
黄洁平等: "β-羟丁酸对高磷诱导的血管钙化的影响", 《岭南急诊医学杂志》, no. 06, 20 December 2019 (2019-12-20), pages 517 - 520 * |
黄湛等: "一氧化氮对成骨细胞样细胞系MC3T3-E1的矿化调控", 《中华老年口腔医学杂志》 * |
黄湛等: "一氧化氮对成骨细胞样细胞系MC3T3-E1的矿化调控", 《中华老年口腔医学杂志》, no. 02, 15 April 2007 (2007-04-15) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113740137A (zh) * | 2021-09-30 | 2021-12-03 | 山东骏腾医疗科技有限公司 | 一种病理组织切片染色试剂盒 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Van De Vlekkert et al. | Analysis of generalized fibrosis in mouse tissue sections with Masson’s trichrome staining | |
Jordan | A Text-book of Histology | |
US11035763B2 (en) | Kit for producing cleared biological specimens and method for producing cleared biological specimens | |
CN102116711A (zh) | 一种大叶藻胚石蜡切片的制作方法 | |
CN103940658A (zh) | 一种组织细胞标本石蜡包埋的制作方法 | |
CN106265740B (zh) | 脐带间充质干细胞联合黄芪多糖在制备治疗高血糖和糖尿病肾病药物中的应用 | |
CN106501053B (zh) | 岩黄连叶片的石蜡切片方法 | |
CN109207545A (zh) | 一种胶原蛋白提取方法 | |
CN111811910A (zh) | 一种石蜡切片钙盐染色套染苏木素-伊红试剂盒及其染色方法 | |
CN109265531A (zh) | 鸡胸软骨肽及其制备方法和应用 | |
Prokopyuk et al. | Safety of placental, umbilical cord and fetal membrane explants after cryopreservation | |
CN103940647A (zh) | 一种中华鳖胚胎期性腺的连续石蜡切片制作方法及其在性别判定中的应用 | |
CN110448617A (zh) | 一种总酸浆苦素提取物的制备方法及其应用 | |
Jirkovská et al. | Spatial arrangement of fetal placental capillaries in terminal villi: a study using confocal microscopy | |
CN111879590A (zh) | 肾活检免疫荧光冰冻剩余组织重制石蜡切片的方法 | |
CN110327341A (zh) | Acss2抑制剂在制备预防和/或治疗糖尿病肾病药物中的应用 | |
CN105548569A (zh) | 一种肾癌患者外周血vegf的检测方法 | |
CN109632420A (zh) | 一种基于水溶性试剂的快速组织透明化的处理方法及其应用 | |
de Laat et al. | The Roach muscle bundle and umbilical cord coiling | |
CN104826164B (zh) | 能在体实现自我重塑的生物人工血管 | |
Robertson | The normal histology and pathology of the neuroglia (in relation specially to mental diseases) | |
Li et al. | Effects of different dehydration methods on the preservation of aortic and renal glycocalyx structures in mice | |
Bereza et al. | Vascular architecture of the human uterine cervix, as assessed in light and scanning electron microscopy | |
Jost et al. | The fine structure of human pseudomembranous trigonitis | |
CN105911281A (zh) | 基于zeb-1和zeb-2作为标记物预警乳腺癌转移的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201023 |